Probiotic normalization of systemic inflammation in siblings of type 1 diabetes patients: an open-label pilot study.

ABSTRACT: The incidence of type 1 diabetes (T1D) has increased, coinciding with lifestyle changes that have likely altered the gut microbiota. Dysbiosis, gut barrier dysfunction, and elevated systemic inflammation consistent with microbial antigen exposure, have been associated with T1D susceptibility and progression. A 6-week, single-arm, open-label pilot trial was conducted to investigate whether daily multi-strain probiotic supplementation could reduce this familial inflammation in 25 unaffected siblings of T1D patients. Probiotic supplementation was well-tolerated as reflected by high participant adherence and no adverse events. Community alpha and beta diversity were not altered between the pre- and post-supplement stool samplings. However, LEfSe analyses identified post-supplement enrichment o

SUBMITTER: Cabrera SM 

PROVIDER: S-EPMC8885673 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature